Participating Companies

3T Biosciences
Provider of medical research and development facilities intended to offer immunotherapeutic services for cancer-related diseases. The company's facilities incorporate synthetic biology and machine learning to discover novel targets in order to cure cancer and other T-cell mediated diseases, enabling patients to receive various cancer disease related treatments. [more information]

Artios Pharma
The Company, founded by SV Health Investors in 2016, is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. [more information]

AsclepiX Therapeutics
AXT107 demonstrated efficacy and durability in rabbit and mouse models that is superior to standard of care Eylea. [more information]

Atomwise
Operator of an artificial intelligence-based biotechnology company intended to help invent new potential medicines for more than 50 disease targets. The company's technology helps in drug hit discovery, binding affinity prediction and toxicity detection, enabling scientists to discover small molecules for the treatment and investigation of human diseases. [more information]

BioSight
Biosight is a private Phase 2 clinical stage biotech company, developing innovative therapeutics for hematological malignancies and disorders. [more information]

Caraway Therapeutics
Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically-defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating autophagy and lysosomal function. [more information]

Carisma Therapeutics Inc.
Developer of cell therapies intended to treat solid tumors by re-engineering macrophages. The company's therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment, enabling solid tumor patients to receive strong cellular immunotherapy and cancer treatments. [more information]

Casma Therapeutics
The company focuses on the autophagy system to improve the cellular process of clearing out unwanted proteins, organelles, and invading pathogens, it also arrests or reverses the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders, and neurodegeneration, enabling physicians to address unmet medical needs and to bring cures to patients with serious diseases. [more information]

Century Therapeutics
The company's drugs are genetically-engineered, iPSC-derived immune effector cell products designed to specifically target hematologic and solid cancers by harnessing the power of adult stem cells, enabling patients to have access to curative therapies for cancer. The funds will be used to advance multiple programs into the clinic for hematologic and solid malignancies. [more information]

Confo Therapeutics
The company is building a portfolio of programs based on its proprietary technology which derives specialized camelid single-domain antibodies which stabilize G-protein coupled receptors (GPCRs) in a conformation of interest for drug discovery, enabling the medical industry to be provided with novel pathway-selective agonists for improved therapeutic intervention. [more information]

Crescendo Biologics
Crescendo Biologics is a clinical stage company developing T cell enhancing therapeutics.
Crescendo’s lead programme, CB307, is a CD137 (4-1BB) x PSMA bispecific. CB307’s unique format delivers tumour-specific killing, while avoiding systemic toxicity, and can be applied to a broad range of PSMA-positive cancer indications. It is designed to cause the proliferation of tumour-specific T cells, creating a safe, broad, longer-lasting anti-tumour response and will be in the clinic in early 2021. [more information]

Elevation Oncology
Our lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions and is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion. [more information]

Eureka Therapeutics
The company's platform is focused on improving the safety profile of T cell therapies and developing novel T cell therapies for the treatment of solid tumors, enabling clients to avail a pipeline of novel cancer therapeutics targeting intracellular oncogenes as well as cell-surface antigens. [more information]

Fog Pharmaceuticals
FogPharma's mission is to drastically reduce the burden of disease on patients and their families by inventing new types of drugs that squelch abnormal physiological processes in ways previously imagined but considered unattainable. [more information]

GentiBio
Operator of a biotherapeutics company intended to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company develops engineered regulatory T cells (EngTregs), thus helping clients by successfully restoring immune tolerance and overcoming major limitations in existing regulatory T-cell therapeutics. [more information]

Glycostem Therapeutics
Glycostem Therapeutics is a Dutch biotech company. Glycostem Therapeutics is the trade name of the legal entity IPD Therapeutics BV, which has been established in December 2007.
Glycostem Therapeutics has developed the world's first GMP compliant NK-cell platform that is ready for industrial scale-up. [more information]

HemoShear Therapeutics
HemoShear Therapeutics discovers novel biological targets and advances drug programs to treat metabolic disorders with significant unmet patient need. The Company's lead programs in propionic and methylmalonic acidemia (rare inborn errors of metabolism) will enter phase 2 studies this year. [more information]

Immuneering
The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies. Immuneering’s leading program, a small molecule in IND-enabling studies that targets MEK, is projected to enter clinical trials in late 2021. Immuneering also has multiple additional preclinical programs in oncology, neuroscience and immuno-oncology. [more information]

IN8bio, Inc.
IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for both of its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma, which is a difficult to treat brain tumor that progresses rapidly, and INB-100 for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation. [more information]

Invetx
Invetx is building the world’s premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. The Invetx team of highly experienced R&D leaders from both human biotech and animal health is supported by best-in-class biotechnology partners and an extensive network of industry experts, veterinary scientists and clinicians. Invetx is a private company headquartered in Boston, Massachusetts. [more information]

ISA Pharmaceuticals BV
is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT®technology. [more information]

Jasper Therapeutics
JJasper is a biotechnology company focused on developing and commercializing safer, more effective conditioning agents to allow for expanded use of curative therapy with stem cell transplantation and gene therapies. Our goal is to make cures possible with hematopoietic cell transplantation and gene therapies for all types of patients, including children and the elderly. [more information]

Jnana
Jnana Therapeutics is a biotechnology company focused on modulating cellular metabolism by opening the solute carrier (SLC) family of metabolite transporters as a target class to develop transformational therapeutics. [more information]

KAHR
The company lead product, DSP107, is a CD47-41BB targeting compound that simultaneously target cancer cells, weaken their innate defenses and activate an effective, local response of both innate (by blocking ‘Don’t eat me’ signals) and adaptive immunity (by providing co-stimulation signal to T and NK cells). [more information]

Kineta Inc.
Kineta (Private) - wholly owned preclinical anti-VISTA (innate immune target) antibody reprograms the tumor microenvironment and is differentiated from other immunotherapies by blocking suppressive cells in cold tumors. $360M+ deal with Genentech for KCP506, Ph1 non-opioid for chronic pain. [more information]

Kriya Therapeutics
The company uses algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies, thereby enabling healthcare institutions to provide transformative new treatments for highly prevalent and severe chronic diseases. [more information]

Locanabio
The company's technology consists of an advanced and powerful modular RNA targeting-effector approach to address the root cause of genetic disease, enabling medical practitioners to optimize and advance therapeutic candidates that are distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. [more information]

MiNa Therapeutics
Developer of therapeutic medicines designed to harness gene activation mechanisms through small activating RNA. The company's technology and clinical know-how transform the therapy landscape of cancer and other severe diseases, enabling doctors and physicians to cure cancer and other severe diseases and develop new medicines that restore normal function to patients' cells. [more information]

Neurona Therapeutics
Our initial aim is to generate therapeutic compositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, we believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. [more information]

NorthSea Therapeutics
First-in class, oral, structurally engineered fatty acids [SEFAs] addressing NASH and associated metabolic disorders via unique targeting of pathways regulating metabolism, oxidative stress, inflammation, and fibrosis. $40m Series B (Jan 2020) with venBio Partners (lead) and Sofinnova Investments. [more information]

Omega Therapeutics
About Omega Therapeutics Omega Therapeutics is a privately held, development-stage biotechnology company pioneering the field of epigenomic programming to precisely regulate and control the human genome to treat and cure disease. [more information]

OncXerna Therapeutics
OncXerna Therapeutics offers a unique approach to precision oncology medicine based on a deep understanding of a patient’s solid tumor microenvironment and “dominant biology” at the RNA level. [more information]

ONK Therapeutics Limited
The lead program, ONKT101, is a dual-targeted NK cell therapy incorporating a CD19 CAR and TRAILv targeting DR5, intended for the treatment of relapsed/refractory B cell malignancies. [more information]

PROSION
A pharmaceutical drug discovery company with proline derived modules (ProMs) as the world’s first PRM structure mimicking building blocks. The company develops a new class of drugs and is able to address yet undruggable considered targets that are related to various indications. For its first of many use-cases, PROSION has already shown a remarkable in vivo effect of its ProM-based anti-metastatic inhibitor – both in pancreatic and breast cancer xenograft rodent models. [more information]

ReAlta Life Sciences
The company's drugs have Complement inhibition (C1), anti-inflammatory, antioxidant and antimicrobial capabilities to provide game-changing therapy for multiple unmet or under-addressed medical needs, enabling healthcare professionals to address life-threatening medical needs through beneficial inhibition of the Complement System and Inflammatory Mechanisms. [more information]

Reistone Biopharma
Collaboration is integral to success, and we are currently looking for either partnership to develop the AD and/or UC or CD indications for phase 3 or out-license the global right excluding China market. [more information]

Saniona
[SANION:ST]
SKr1,235 MM MCap
A research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. [more information]

Scribe Therapeutics
Scribe Therapeutics is a molecular engineering company focused on building best-in-class in vivo therapies to permanently treat the underlying cause of disease. [more information]

Sirnaomics
Developer of novel targeted therapeutics intended to treat critical human diseases. The company's therapeutics leverage proprietary Polypeptide Nano-Particle (PNP) technology to access the tumor micro-environment (TME), as well as various cell types in the liver, enabling medical practitioners to treat patients effectively. erence technology. [more information]

Synthekine
The company is generating an array of "synthetic" cytokines that possess greater cell selectivity, bias cell signaling, and/or possess completely new biological activities relative to their native counterpart, enabling potential treatment of a range of diseases, from cancer to autoimmune disorders. [more information]

Triplet Therapeutics
Triplet is pursuing a transformative approach to develop treatments for repeat expansion disorders, a group of more than 40 known genetic diseases associated with expanded DNA nucleotide repeats including Huntington’s disease, myotonic dystrophy and various spinocerebellar ataxias. [more information]

Triumvira Immunologics
The company's proprietary technology recruits the entire natural T-cell receptor and functions independent of the Major Histocompatibility Complex (MHC), potentially allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer, thereby providing medical practitioners and patients with new hope to deal with life-threatening diseases. [more information]

Tvardi Therapeutics
The company's services focuse on the key signaling molecule, STAT3, which is positioned at the intersection of many signaling pathways controlling gene networks integral to the survival and immune sequestration of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic conditions, enabling patients to get medicines for the treatment of breast cancer and lung cancer. [more information]

Versantis
Versantis is a phase 2a pharmaceutical company developing a new generation of orphan medicines to revolutionize the care of patients with liver diseases. Versantis is developing its lead candidate, VS-01, as a first-line medication for the acute support of cirrhotic and metabolic decompensations. VS-01 received Orphan Drug designation from both FDA and EMA. [more information]

Verve Therapeutics
Verve is developing medicines, administered once in life, to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels and thereby treat coronary heart disease. [more information]

Xilio Therapeutics
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. [more information]